# Cosentyx (secukinumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/secukinumab

> The FDA approved Cosentyx (secukinumab), sponsored by NOVARTIS AG (NVS), on October 6, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cosentyx (secukinumab) |
| Codes | AIN457 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [Polymyalgia Rheumatica](https://sec-api.dev/indications/polymyalgia-rheumatica), Giant Cell Arteritis |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### January 29, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20200129, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### June 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### May 28, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20210528, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### December 22, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20211222, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22
- openFDA Drugs@FDA: "BLA125504 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20211222, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### May 11, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20230511, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### October 6, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761349 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20231006, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761349%22

### October 31, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-63 (Efficacy): submission_status AP, submission_status_date 20231031, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### September 10, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Polymyalgia Rheumatica.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05767034 (Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-10 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05767034

### February 24, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Giant Cell Arteritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05380453 (Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05380453

### March 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-91 (Efficacy): submission_status AP, submission_status_date 20260312, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### April 17, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125504 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20260417, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22
- openFDA Drugs@FDA: "BLA125504 SUPPL-98 (Efficacy): submission_status AP, submission_status_date 20260417, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22

### October 15, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761349 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20261015, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761349%22

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Polymyalgia Rheumatica.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06331312 (Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06331312

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Polymyalgia Rheumatica.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06331312 (Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06331312

## Same indication

- [Kevzara (sarilumab)](https://sec-api.dev/pdufa/sarilumab) (SNY)

Calendar months: [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/secukinumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cosentyx (secukinumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/secukinumab

```bibtex
@misc{secapidev_pdufa_secukinumab_20261116,
  title        = {Cosentyx (secukinumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/secukinumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_secukinumab_20261116","title":"Cosentyx (secukinumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/secukinumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
